Marc J. Wolfgang
Directeur/Membre du Conseil chez Nanomedicines Alliance
Profil
Marc J.
Wolfgang is currently the Vice Chairman at Nanomedicines Alliance.
Previously, he held positions such as Senior Quality Director at Momenta Pharmaceuticals, Principal at Biogen MA, Associate General Counsel at Millennium Pharmaceuticals, and General Counsel at ConjuChem, among others.
He also served as VP-Pharmaceutical Sciences & Manufacturing at Cerulean Pharma from 2015 to 2016.
Wolfgang received his undergraduate degrees from Montclair State University and The Pennsylvania State University.
Postes actifs de Marc J. Wolfgang
Sociétés | Poste | Début |
---|---|---|
Nanomedicines Alliance | Directeur/Membre du Conseil | - |
Anciens postes connus de Marc J. Wolfgang
Sociétés | Poste | Fin |
---|---|---|
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/11/2016 |
Boehringer Ingelheim Animal Health USA, Inc.
Boehringer Ingelheim Animal Health USA, Inc. BiotechnologyHealth Technology Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA. | Corporate Officer/Principal | - |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
ConjuChem, Inc.
ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. | Conseiller Juridique Général | - |
Formation de Marc J. Wolfgang
Montclair State University | Undergraduate Degree |
The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 7 |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
ConjuChem, Inc.
ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. | Health Technology |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Boehringer Ingelheim Animal Health USA, Inc.
Boehringer Ingelheim Animal Health USA, Inc. BiotechnologyHealth Technology Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA. | Health Technology |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
Nanomedicines Alliance |